Marco De Zuani

Marco De Zuani

Auto-generated profile, based on publicly available information

Marco De Zuani

International Clinical Research Center St. Anne's University Hospital Brno Czech Republic

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MZMarco De Zuani
Marco De Zuani
HXHaoliang Xue
Haoliang Xue
JPJun Sung Park
Jun Sung Park
SDStefan C. Dentro
Stefan C. Dentro
ZSZaira Seferbekova
Zaira Seferbekova
ACAna Cvejic
Ana Cvejic
Lung cancer is the second most frequently diagnosed cancer and the leading cause of cancer-related mortality worldwide. Tumour ecosystems feature diverse immune cell types. Myeloid cells, in particular, are prevalent and have a well-established role in promoting the disease. In our study, we profile approximately 900,000 cells from 25 treatment-naive patients with adenocarcinoma and squamous-cell carcinoma by single-cell and spatial transcriptomics. We note an inverse relationship between anti-inflammatory macrophages and NK cells/T cells, and with reduced NK cell cytotoxicity within the tumour. While we observe a similar cell type composition in both adenocarcinoma and squamous-cell carcinoma, we detect significant differences in the co-expression of various immune checkpoint inhibitors. Moreover, we reveal evidence of a transcriptional “reprogramming” of macrophages in tumours, shifting them towards cholesterol export and adopting a foetal-like transcriptional signature which promotes iron efflux. Our multi-omic resource offers a high-resolution molecular map of tumour-associated macrophages, enhancing our understanding of their role within the tumour microenvironment.

16 January 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
SMSilvia Moretti
Silvia Moretti
GRGiorgia Renga
Giorgia Renga
VOVasileios Oikonomou
Vasileios Oikonomou
CGClaudia Galosi
Claudia Galosi
MPMarilena Pariano
Marilena Pariano
LRLuigina Romani
Luigina Romani
T helper 9 (Th9) cells contribute to lung inflammation and allergy as sources of interleukin-9 (IL-9). However, the mechanisms by which IL-9/Th9 mediate immunopathology in the lung are unknown. Here we report an IL-9-driven positive feedback loop that reinforces allergic inflammation. We show that IL-9 increases IL-2 production by mast cells, which leads to expansion of CD25+type 2 innate lymphoid cells (ILC2) and subsequent activation of Th9 cells. Blocking IL-9 or inhibiting CD117 (c-Kit) signalling counteracts the pathogenic effect of the described IL-9-mast cell-IL-2 signalling axis. Overproduction of IL-9 is observed in expectorates from cystic fibrosis (CF) patients, and a sex-specific variant of IL-9 is predictive of allergic reactions in female patients. Our results suggest that blocking IL-9 may be a therapeutic strategy to ameliorate inflammation associated with microbial colonization in the lung, and offers a plausible explanation for gender differences in clinical outcomes of patients with CF.

1 May 2018 in Cell Reports
Verified
Journal Article
Open access
GRGiorgia Renga
Giorgia Renga
SMSilvia Moretti
Silvia Moretti
VOVasileios Oikonomou
Vasileios Oikonomou
MBMonica Borghi
Monica Borghi
TERESA ZELANTETERESA ZELANTE
TERESA ZELANTE
LRLuigina Romani
Luigina Romani
Candida albicans is implicated in intestinal diseases. Identifying host signatures that discriminate between the pathogenic versus commensal nature of this human commensal is clinically relevant. In the present study, we identify IL-9 and mast cells (MCs) as key players of Candida commensalism and pathogenicity. By inducing TGF-β in stromal MCs, IL-9 pivotally contributes to mucosal immune tolerance via the indoleamine 2,3-dioxygenase enzyme. However, Candida-driven IL-9 and mucosal MCs also contribute to barrier function loss, dissemination, and inflammation in experimental leaky gut models and are upregulated in patients with celiac disease. Inflammatory dysbiosis occurs with IL-9 and MC deficiency, indicating that the activity of IL-9 and MCs may go beyond host immunity to include regulation of the microbiota. Thus, the output of the IL-9/MC axis is highly contextual during Candida colonization and reveals how host immunity and the microbiota finely tune Candida behavior in the gut.

9 November 2018 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MZMarco De Zuani
Marco De Zuani
CSChiara Dal Secco
Chiara Dal Secco
Barbara FrossiBarbara Frossi
Barbara Frossi

1 January 2020 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
SJShyam Sushama Jose
Shyam Sushama Jose
MZMarco De Zuani
Marco De Zuani
FTFederico Tidu
Federico Tidu
MHMarcela Hortova-Kohoutkova
Marcela Hortova-Kohoutkova
LPLucia Pazzagli
Lucia Pazzagli
JFJan Frič
Jan Frič
Objectives: The activation of immune responses in mucosal tissues is a key factor for the development and sustainment of several pathologies including infectious diseases and autoimmune diseases. However, translational research and personalised medicine struggle to advance because of the lack of suitable preclinical models that successfully mimic the complexity of human tissues without relying on in vivo mouse models. Here, we propose two in vitro human 3D tissue models, deprived of any resident leucocytes, to model mucosal tissue inflammatory processes.Methods: We developed human 3D lung and intestinal organoids differentiated from induced pluripotent stem cells to model mucosal tissues. We then compared their response to a panel of microbial ligands and investigated their ability to attract and host human primary monocytes.Results: Mature lung and intestinal organoids comprised epithelial (EpCAM+) and mesenchymal (CD73+) cells which responded to Toll‐like receptor stimulation by releasing pro‐inflammatory cytokines and expressing tissue inflammatory markers including MMP9, COX2 and CRP. When added to the organoid culture, primary human monocytes migrated towards the organoids and began to differentiate to an ‘intermediate‐like’ phenotype characterised by increased levels of CD14 and CD16.Conclusion: We show that human mucosal organoids exhibit proper immune functions and successfully mimic an immunocompetent tissue microenvironment able to host patient‐derived immune cells. Our experimental set‐up provides a novel tool to tackle the complexity of immune responses in mucosal tissues which can be tailored to different human pathologies.

8 June 2020 in Shock
Verified
Journal Article
Open access
MHMarcela Hortova-Kohoutkova
Marcela Hortova-Kohoutkova
FTFederico Tidu
Federico Tidu
MZMarco De Zuani
Marco De Zuani
VŠVladimír Šrámek
Vladimír Šrámek
MHMartin Helán
Martin Helán
JFJan Frič
Jan Frič
Phagocytosis is a complex process by which cells within most organ systems remove pathogens and cell debris. Phagocytosis is usually followed by inflammatory pathway activation, which promotes pathogen elimination and inhibits pathogen growth. Delayed pathogen elimination is the first step in sepsis development and a key factor in sepsis resolution. Phagocytosis thus has an important role during sepsis and likely contributes to all of its clinical stages. However, only a few studies have specifically explored and characterized phagocytic activity during sepsis. Here, we describe the phagocytic processes that occur as part of the immune response preceding sepsis onset and identify the elements of phagocytosis that might constitute a predictive marker of sepsis outcomes. First, we detail the key features of phagocytosis, including the main receptors and signaling hallmarks associated with different phagocytic processes. We then discuss how the initial events of phagosome formation and cytoskeletal remodeling might be associated with known sepsis features, such as a cytokine-driven hyperinflammatory response and immunosuppression. Finally, we highlight the unresolved mechanisms of sepsis development and progression and the need for cross-disciplinary approaches to link the clinical complexity of the disease with basic cellular and molecular mechanisms.